Harbour BioMed-B (02142) partner Spruce spins off CRHX-101 project to Adrenyx; Adrenyx plans Nasdaq listing in the first half of 2027

date
18/11/2026
Zhitong Finance APP News, HBM Holdings-B (02142) announces that the Company's partner Spruce Biosciences Inc. (Nasdaq stock code: SPRB) (Spruce) has spun off its CRHX-101 (also known as HBM9013/HAT001/SPR-202) program into Spruce's newly established wholly-owned subsidiary Adrenyx Biosciences, Inc. (Adrenyx), and Adrenyx is expected to list on Nasdaq in the first half of 2027. Upon completion of the plan to distribute shares of Adrenyx common stock to Spruce shareholders on a pro rata basis, HBM Holdings expects to hold equity interests in both Spruce and Adrenyx simultaneously. CRHX-101 is a monoclonal antibody designed and developed for the treatment of congenital adrenal hyperplasia. Adrenyx intends to submit an Investigational New Drug application for CRHX-101 to the U.S. Food and Drug Administration and thereafter initiate clinical development.